Study ALK+ (N)/Total (N) Efficacy
Studies with no control or adjustment for confounding factors
Shaw et al. [15] 17 ALK+ /96
never/light smokers, stage IV 		Median OS:
• 20 months in ALK+a
• 32 months in EGFR mu (p = 0.468 vs.ALK+)
• 16 months in ALK−/EGFR WT (p = 0.152 vs.ALK+)
Shaw et al. [2] 36 ALK+/356
advanced 		Median OS:
• 20 months in ALK+
• 15 months in ALK−/EGFR WT (p = 0.244 vs.ALK+)
Takeda et al. [16] 18 ALK+/200
advanced non squamous cases 		Median OS† :
• 15.7 months in ALK+
• 24.8 months in EGFR mu (p = 0.135 vs. ALK+)
• 15.2 months in ALK−/EGFR WT (p = 0.591 vs. ALK+)
Wang et al. [17] 9 ALK+/113
stage IV 		Median OS:
• 19.27 months in ALK+
• 23.13 months in EGFR mu
• 18.93 months in ALK−/EGFR WT (p = 0.481 vs. ALK+ and EGFR mu)
Hayashi et al. [18] 3 ALK+/37
locally advanced
adeno cases 		Median OS:
• 7.7 months in ALK+
• 67.5 months in EGFR mu
• 42.6 months in ALK−/EGFR WT (p = 0.007 vs. ALK+)
Martinez et al. [8] 7 ALK+/99
Non squamous ,all stages 		Median OS:
• not reached in ALK+b
• 15.7 months in EGFR mu
• 4.5 months in ALK−/EGFR WT (p =0.103 vs. ALK+)
Paik et al. [19] 28 ALK+/735
stage I-III 		Median OS:
• 97.7 months in ALK+
• 78.9 months in ALK− (p = 0.10 vs. ALK+)
Fukui et al. [20] 28 ALK+/720
Adeno resected cases,
all stages 		5-year OS rate:
• 81%  in ALK+
• 77%  in ALK− (p = 0.76 vs. ALK+)
Studies with control or adjustment for confounding factors
Lee et al. [6] 23 ALK+ /262
non-squamous EGFR WT or TKI non-responders,
stage IIIb–IVb 		Median OS:
• 12.23 months in ALK+
• 29.63 months in EGFR mu (p = 0.001 vs. ALK+)
• 19.33 months in WT/WT (p = 0.127 vs. ALK+)
Yang et al. [4] 22 ALK+/296never-smoker, adenocasesc
9=stage I/II
7=stage III
6=stage IV 		DFS not reported in either ALK+ or ALK− groups
(2-fold greater risk of progression or recurrence within 5 yrs of diagnosis reported in ALK+ vs.ALK− cases, p=0.004)
Kim et al. [5] 13 ALK+/229
never-smokers, all stagesd		 Median OS:
• 14.3 months in ALK+
• 37.2 months in EGFR mu (p = 0.001 vs. ALK+)
• 33.3 months in ALK−/EGFR WT/KRAS WT (p = 0.016 vs. ALK+)
Wu et al. [21] 39 ALK+/116
adeno cases, stage IVe		 Median OS:
• 14.7 months in ALK+
• 10.3 months in ALK−/EGFR WT (p = 0.011 vs. ALK+)
a7/17 and b4/7 ALK+ patients enrolled in crizotinib trial; b Matched to 46 EGFR mu and 46WT/W Ton age at dx, sex, stage, smoking status; c Adjusted for age at dx, sex, tumour grade, tx modality; d Adjusted for age, sex, stage, tx; e Adjusted for age, sex, smoking status, PS, treatment; † OS was calculated from the date of chemotherapy; mu, mutated; adeno, adenocarcinoma; dx , diagnosis; tx, treatment; TKI, tyrosine kinase inhibitor; WT, wild type; OS, overall survival; DFS, disease-free survival.
Table 1: Overall Survival.